Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice

Authors:

Abstract
Development of SARS-CoV-2 vaccines that protect vulnerable populations is a public health priority. Here, we took a systematic and iterative approach by testing several adjuvants and SARS-CoV-2 antigens to identify a combination that elicits antibodies and protection in young and aged mice. While demonstrating superior immunogenicity to soluble receptor-binding domain (RBD), RBD displayed as a protein nanoparticle (RBD-NP) generated limited antibody responses. Comparison of multiple adjuvants including AddaVax, AddaS03, and AS01B in young and aged mice demonstrated that an oil-in-water emulsion containing carbohydrate fatty acid monosulphate derivative (CMS:O/W) most effectively enhanced RBD-NP-induced cross-neutralizing antibodies and protection across age groups. CMS:O/W enhanced antigen retention in the draining lymph node, induced injection site, and lymph node cytokines, with CMS inducing MyD88-dependent Th1 cytokine polarization. Furthermore, CMS and O/W synergistically induced chemokine production from human PBMCs. Overall, CMS:O/W adjuvant may enhance immunogenicity and protection of vulnerable populations against SARS-CoV-2 and other infectious pathogens.
Funding Information
  • U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (HHSN272201400052C, 75N93019C00044, HHSN272201800047C, 1R21AI137932-01A1, 75N93019C00044)
  • U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
  • U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
  • Massachusetts Consortium on Pathogenesis Readiness
  • U.S. Department of Health & Human Services | National Institutes of Health (1R01DK115217, 1R01AI165505, 75N93019C00044, AI148166, HHSN272201400007C)
  • U.S. Department of Health & Human Services | National Institutes of Health
  • U.S. Department of Health & Human Services | National Institutes of Health
  • U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority (ASPR-20-01495)
  • United States Department of Defense | Defense Advanced Research Projects Agency (ASPR-20-01495)
  • U.S. Department of Health & Human Services | National Institutes of Health
  • U.S. Department of Health & Human Services | National Institutes of Health
  • U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
  • U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases

This publication has 73 references indexed in Scilit: